Daniel Geffken, CFO, acquired 125,000 Common Shares on a direct ownership basis at a price of $0.250 through a prospectus or prospectus exempt offering on August 9th, 2017. This represents a $31,250 investment into the company's shares and an account share holdings change of 55.3%.
In addition, Elliot Paul Goldstein, CEO and Director, acquired 100,000 Common Shares and 50,000 Warrants with an exercise price of $0.300 for 60 months, subject to acceleration. This represents a $25,000 investment into the company's shares and an account share holdings change of 1.5%.
On the same terms, Eugene Warren Williams, a Director, acquired 100,000 Common Shares and 50,000 Warrants on a direct ownership basis. This represents a $25,000 investment into the company's shares and an account share holdings change of 1.4%. Patrick D. Kirwin, a Director, acquired 80,000 Common Shares and 40,000 Warrants on a control or direction basis for registered holder Jeananne Kirwin. This represents a $20,000 investment into the company's shares and an account share holdings change of 10.5%.
ProMIS Neurosciences is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
ProMIS Neurosciences Inc, formerly Amorfix Life Sciences Ltd, is a Canada-based development-stage biotech company. The Company discovers and develops precision therapeutics with companion diagnostics for early detection and treatment of neurodegenerative diseases, in particular Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The assays are developed using its technologies, Epitope Protection and AMFIA. It is developing therapies targeting misfolded, neurotoxic forms of Amyloid beta in AD and superoxide dismutase 1 (SOD1) in ALS. The Company focuses to use its platform to discover further targets for precision medicine solutions through identification of target epitopes on other misfolded strains of Amyloid beta. The Company focuses to evaluate targets on misfolded strains of tau, another protein implicated in neurodegenerative diseases, including Alzheimer's. The Company has not generated any product revenues.
No Comments